Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
2003;285:R470R478
How It Works Activates both GLP-1 and GIP receptors for a broader metabolic impact Reduces appetite and increases satiety through two hormonal pathways Enhances insulin sensitivity more aggressively than GLP-1 alone Supports reduction of visceral fat the deep abdominal fat most strongly associated with metabolic disease Improves blood sugar regulation through a dual insulin-stimulating mechanism Clinical Results In the SURMOUNT-1 trial, Tirzepatide produced average weight loss of up to 20% of body weight outperforming Semaglutide in head-to-head comparisons
If you have specific questions regarding candidacy, contact our office at 919-569-5943
Tirzepatide (Mounjaro, Eli Lilly), has not been recommended in draft guidance issued by NICE on 27 June for treating type 2 diabetes in adults alongside diet and exercise
US$ 26.17
US$ 28.86
US$ 23.72
